Our Pricing

Order Wegovy Online UK: Clinical-Grade Weight Loss Treatment

Published on: June 03, 2026

When you order Wegovy online UK through Cured Pharmacy, you receive genuine semaglutide injections from £79.00 dispensed by our UK-registered clinical team following a comprehensive online assessment. Our service combines transparent upfront pricing with next-day discreet delivery, ensuring you access MHRA-licensed weight loss treatment without compromising on clinical safety or convenience.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your body produces after eating [1]. This medication works through three complementary mechanisms: it slows gastric emptying to prolong fullness, reduces appetite signals in the brain, and improves insulin sensitivity to stabilise blood glucose levels.

In the landmark STEP 1 clinical trial involving 1,961 adults with obesity, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 83.5% of participants on semaglutide lost at least 5% of their initial body weight—a threshold associated with meaningful metabolic health improvements—versus just 31.1% in the placebo group.

The medication is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Your UK prescriber will initiate treatment at a low dose (0.25mg weekly) and gradually increase it over 16-20 weeks to the maintenance dose of 2.4mg, minimising gastrointestinal side effects whilst optimising therapeutic response [2].

Order Wegovy Online UK: The Clinical Assessment Process

All prescription weight loss treatments dispensed by Cured Pharmacy require completion of a clinical assessment by a UK-registered prescriber, in full compliance with General Pharmaceutical Council (GPhC) and MHRA regulations. Our online consultation takes under three minutes and collects essential medical information including your weight history, current medications, cardiovascular health, and any contraindications to GLP-1 therapy.

Our clinical team, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews each assessment individually. Wegovy is typically considered appropriate for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea—criteria aligned with NICE guidance [3].

If approved, your prescription is processed immediately and your medication dispatched from our UK pharmacy with next-day delivery options available. All packaging is 100% discreet with no external indication of contents, and every Wegovy pen is sourced directly from licensed UK wholesalers to guarantee authenticity.

Who Should Not Use Wegovy

Wegovy is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as GLP-1 agonists have been associated with thyroid C-cell tumours in rodent studies [2]. It should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment. Your prescriber will assess these factors during your consultation to ensure suitability.

Wegovy vs Mounjaro: Comparing GLP-1 Weight Loss Treatments

Both Wegovy and Mounjaro are injectable medications licensed by the MHRA for chronic weight management, but they differ in their pharmacological mechanisms and clinical efficacy profiles. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist available in the UK.

Head-to-head trial data suggests tirzepatide produces greater average weight reduction than semaglutide. In the SURPASS-2 trial, participants on the highest tirzepatide dose (15mg) achieved mean weight loss of 12.4kg compared to 6.2kg with semaglutide 1mg over 40 weeks [4]. However, direct comparison is complicated by differing doses and study populations—the 2.4mg Wegovy dose used for obesity was not included in this diabetes-focused trial.

The choice between treatments depends on individual response, tolerability, and clinical context. Some patients experience better gastrointestinal tolerance with one medication over the other, whilst prescribers may favour Mounjaro for patients with concurrent type 2 diabetes given its superior glycaemic control in trials [4]. Both require similar injection frequency (once weekly) and gradual dose escalation protocols.

Alternative Weight Loss Medications Available

Beyond GLP-1 therapies, Cured Pharmacy dispenses several other MHRA-licensed weight management treatments. Saxenda (liraglutide) is a daily GLP-1 injection suitable for patients who prefer more frequent, lower-volume injections. Orlistat-based medications (including Xenical, Alli, and generic orlistat) work through a completely different mechanism—blocking dietary fat absorption in the intestine—and may be appropriate for patients with contraindications to GLP-1 therapy. Mysimba combines naltrexone and bupropion to reduce appetite through central nervous system pathways. Your prescriber will recommend the most suitable option based on your medical profile and treatment goals.

Wegovy Dosing Schedule and Administration Technique

The standard Wegovy titration schedule begins with 0.25mg once weekly for four weeks, increasing to 0.5mg for four weeks, then 1mg for four weeks, followed by 1.7mg for four weeks, before reaching the maintenance dose of 2.4mg weekly [2]. This gradual escalation minimises the incidence and severity of gastrointestinal side effects—the most common reason for treatment discontinuation in clinical trials.

Each Wegovy pen is pre-filled and designed for single use, with a hidden needle that automatically retracts after injection. Before injecting, allow the pen to reach room temperature for 30 minutes, inspect the solution for clarity (it should be colourless to pale yellow), and select an injection site with adequate subcutaneous tissue. Rotate injection sites weekly to reduce lipodystrophy risk, and avoid injecting into areas with skin changes, bruising, or scarring.

If you miss a dose and fewer than five days have passed, administer it as soon as you remember. If more than five days have elapsed, skip the missed dose and resume your regular schedule—do not double dose. Missing multiple consecutive doses may require restarting the titration schedule at a lower dose to avoid gastrointestinal intolerance; consult your prescriber if this occurs.

Managing Side Effects When You Order Wegovy Online UK

In the STEP clinical trial programme, the most frequently reported adverse events with Wegovy were gastrointestinal: nausea (44% vs 16% placebo), diarrhoea (30% vs 16%), vomiting (24% vs 6%), and constipation (24% vs 11%) [1]. These effects typically emerge during dose escalation phases and diminish with continued use as physiological adaptation occurs.

Practical strategies to minimise gastrointestinal symptoms include eating smaller, more frequent meals rather than large portions; avoiding high-fat, greasy, or heavily spiced foods; staying well-hydrated throughout the day; and injecting at a consistent time when you can rest if nausea occurs. Ginger tea, peppermint, and over-the-counter antiemetics may provide symptomatic relief, though discuss these with your prescriber before use.

Rare but serious adverse events include pancreatitis (discontinue immediately if you experience severe, persistent abdominal pain radiating to the back), gallbladder disease, acute kidney injury (usually secondary to dehydration from vomiting/diarrhoea), and hypoglycaemia when used with insulin or sulfonylureas [2]. Contact your prescriber urgently if you develop symptoms suggestive of these complications.

When to Contact Your Prescriber

Seek immediate medical advice if you experience severe abdominal pain that does not resolve, persistent vomiting preventing fluid intake, visual changes, rapid heartbeat, or signs of allergic reaction (rash, swelling, difficulty breathing). Less urgent but important symptoms to report include ongoing nausea beyond the first month of a new dose, changes in mood or suicidal ideation, or inability to tolerate dose escalation. Our clinical team at Cured Pharmacy remains available via phone (+44 116 4646009) for post-dispensing queries and clinical support throughout your treatment journey.

Wegovy UK Next Day Delivery and Ongoing Supply

Once your clinical assessment is approved and prescription issued, Cured Pharmacy dispatches your Wegovy pens via tracked courier with next-day delivery options available across mainland UK. Each pen must be refrigerated upon arrival (2°C to 8°C) and can be stored for up to 28 days at room temperature (below 30°C) once in use—useful for travel or workplace convenience.

Wegovy is intended as a long-term treatment for chronic weight management, not a short-term intervention. Clinical trials demonstrate that discontinuing semaglutide typically results in weight regain, with STEP 1 extension data showing participants regained approximately two-thirds of lost weight within one year of stopping treatment [5]. Sustained results require ongoing medication alongside behavioural modifications including dietary changes and increased physical activity.

To ensure uninterrupted supply, we recommend reordering two weeks before your current prescription expires. Our system can send automated reminders if you opt in during checkout. Should UK supply constraints arise—as occurred intermittently in 2023-2024 due to global demand—our clinical team will contact you proactively to discuss alternative GLP-1 options or temporary bridging strategies to maintain your treatment continuity and minimise weight regain risk.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for Managing Overweight and Obesity [TA875]. NICE. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modifications, and physical activity levels.